+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 66 Pages
  • August 2023
  • GlobalData
  • Biocon
  • ID: 4319030
Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It has a manufacturing facility and R&D center at BioXcell, Malaysia. It operates overseas offices in the UK, Ireland, the US, Switzerland, Dubai and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd Key Recent Developments

  • May 20, 2023: Biocon's API facility at Hyderabad concludes USFDA inspection, with zero observations
  • Mar 28, 2023: Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia' Award
  • Feb 14, 2023: Biocon Q3FY23 revenue at Rs 3,020 Cr, up 36%; biosimilars up 54%; research services up 23%; generics up 18%
  • Dec 05, 2022: Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Biocon Ltd - Key Facts
  • Biocon Ltd - Key Employees
  • Biocon Ltd - Key Employee Biographies
  • Biocon Ltd - Major Products and Services
  • Biocon Ltd - History
  • Biocon Ltd - Company Statement
  • Biocon Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Biocon Ltd - Business Description
  • Business Segment: Biosimilars
  • Overview
  • Performance
  • Business Segment: Generics
  • Overview
  • Performance
  • Business Segment: Novel Biologics
  • Overview
  • Performance
  • Business Segment: Research Services
  • Overview
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Ireland
  • Performance
  • Geographical Segment: Rest of the world
  • Performance
  • Geographical Segment: United States of America
  • Performance
  • R&D Overview
  • Biocon Ltd - Corporate Strategy
  • Biocon Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Biocon Ltd - Strengths
  • Biocon Ltd - Weaknesses
  • Biocon Ltd - Opportunities
  • Biocon Ltd - Threats
  • Biocon Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Biocon Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 20, 2023: Biocon’s API facility at Hyderabad concludes USFDA inspection, with zero observations
  • Mar 28, 2023: Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
  • Feb 14, 2023: Biocon Q3FY23 revenue at Rs 3,020 Cr, up 36%; biosimilars up 54%; research services up 23%; generics up 18%
  • Dec 05, 2022: Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
  • Nov 14, 2022: Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
  • Sep 23, 2022: Biocon Receives Form 483 for its API & Drug Manufacturing Facility at Iskandar Puteri, Malaysia
  • Sep 23, 2022: Biocon Receives Form 483 for its API Manufacturing Facility at 20th KM Hosur Road, Bengaluru, India
  • Sep 23, 2022: Biocon Receives Form 483 for its API & Drug Manufacturing Facility at Bommasandra-Jigani Link Road, Bengaluru, India
  • Sep 15, 2022: Equillium announces abstract accepted for presentation at ACR Convergence 2022
  • Aug 05, 2022: Biocon Sdn. Bhd. enters Malaysia Book of Records as the first & the largest integrated insulin manufacturing facility
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Biocon Ltd, Key Facts
  • Biocon Ltd, Key Employees
  • Biocon Ltd, Key Employee Biographies
  • Biocon Ltd, Major Products and Services
  • Biocon Ltd, History
  • Biocon Ltd, Other Locations
  • Biocon Ltd, Subsidiaries
  • Biocon Ltd, Joint Venture
  • Biocon Ltd, Key Competitors
  • Biocon Ltd, Ratios based on current share price
  • Biocon Ltd, Annual Ratios
  • Biocon Ltd, Interim Ratios
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Biocon Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Biocon Ltd, Performance Chart (2019 - 2023)
  • Biocon Ltd, Ratio Charts
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Piramal Enterprises Ltd
  • Bharat Immunologicals and Biologicals Corp Ltd
  • Morepen Laboratories Ltd
  • Serum Institute of India Pvt Ltd
  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Panacea Biotec Ltd
  • Panacea Biotec Ltd
  • Morepen Laboratories Ltd
  • Piramal Enterprises Ltd
  • Bharat Immunologicals and Biologicals Corp Ltd
  • Serum Institute of India Pvt Ltd
  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd